…by directly killing tumour cells combined with provoking an immune attack

We are a newly formed research-based company that strives to discover novel cancer therapies. Our goal is it to develop small-molecule based cancer therapies that limit tumour-autonomous growth and/or stimulate the immune system to attack the tumour.

On the tumour-autonomous side, we pursue a combination of epigenetic and other intracellular targets to limit cancer growth.

On the immune side, we target LXR, a well-known nuclear receptor, to reduce tumour- associated immunosuppressive myeloid-derived suppressor cells (MDSCs). This empowers patient T-cells to actively attack the tumor. This approach should productively combine with existing T-cell enhancing checkpoint inhibitor therapies.

Finally, we have discovered a new approach to inhibit NF-kappa B dependent inflammation. We will exploit this novel promising mechanism in three areas:

1. Limiting life-threatening, cytokine storms induced by COVID-19 and by other infections
2. targeting NF-kappa B activity in inflammation dependent cancers, in particular in multiple myeloma
3. treating chronic inflammatory disorders